Sofosbuvir 400 mg and Velpatasvir 100 mg Tablets

Get a Price/Quote

MOQ : 100 Packs

Sofosbuvir 400 mg and Velpatasvir 100 mg Tablets Specification

Salt Composition
Sofosbuvir 400 mg & Velpatasvir 100 mg

Dosage Form
Tablets

Indication
Chronic Hepatitis C Virus (HCV) Infection

Enzyme Types
NS5A and NS5B Polymerase Inhibitors

Feature
Once daily, pangenotypic, oral fixed-dose combination

Ingredients
Sofosbuvir, Velpatasvir, Excipients

Application
Antiviral Therapy

Physical Color/Texture
Film-coated, oval-shaped tablets

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits HCV replication by targeting viral polymerase and NS5A protein

Storage Instructions
Store below 30C, protect from moisture and light

Shelf Life
24-36 months

Prescription Type
Prescription only

Administration Route
Oral

Drug Interactions
May interact with rifampin, St. John's wort, certain anticonvulsants, antacids

Contraindications
Known hypersensitivity to either component or excipients

Packaging
28 tablets per bottle (typical commercial pack)

Strength
Sofosbuvir 400 mg and Velpatasvir 100 mg per tablet

Pregnancy Category
Consult physician (safety not well-established in pregnancy)

Regulatory Approval
Approved by major health authorities for use in HCV

Marketed By
Licensed pharmaceutical companies

Patient Age Group
Adults

Tablet Marking/Imprint
Typically marked for identification (varies by manufacturer)

Sofosbuvir 400 mg and Velpatasvir 100 mg Tablets Trade Information

Minimum Order Quantity
100 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
10 Days

Main Domestic Market
All India

About Sofosbuvir 400 mg and Velpatasvir 100 mg Tablets

Experience the latest in antiviral therapy with Sofosbuvir 400 mg and Velpatasvir 100 mg Tablets-a venerable, elite combination designed to offer pivotal efficacy against chronic Hepatitis C Virus (HCV) infection. This triumphant fixed-dose formulation features film-coated, oval tablets, each dose marking a milestone in pangenotypic treatment. Marketed exclusively by licensed pharmaceutical companies, these tablets act by inhibiting both NS5A and NS5B enzymes, targeting viral replication at its core. Available in secure 28-tablet bottles, these prescription-only tablets boast a shelf life of 24-36 months and are ideal for adult patients seeking reliable, once-daily oral therapy.

Targeted Antiviral Therapy: Features and Advantages

Sofosbuvir 400 mg and Velpatasvir 100 mg Tablets are intended for oral use in adults with chronic HCV infection. Their competitive advantage lies in their pangenotypic action, enabling a broad-spectrum application across various HCV genotypes. Usage is straightforward-once daily administration simplifies patient adherence. The site of action is hepatic, where the elite dual inhibition of HCV enzymes effectively disrupts viral replication, providing patients a pivotal, streamlined route to viral clearance.

Logistics, Market Access, and Cost Considerations

These tablets are generally supplied via prominent FOB ports in India, facilitating efficient transportation and prompt delivery across the main domestic markets. Expenditure assessment is optimized for volume and reliability, while valuation protocols ensure consistent quality with each batch. Payment terms are vendor-specific, typically supporting secure transaction methods for suppliers and traders. These logistics and cost advantages cement the product's status as a valued solution in the pharmaceutical supply chain.

FAQ's of Sofosbuvir 400 mg and Velpatasvir 100 mg Tablets:

Q: How should Sofosbuvir 400 mg and Velpatasvir 100 mg Tablets be taken for best results?

A: For optimal efficacy, take one tablet orally once daily with or without food, strictly following your physician's prescription and guidance.

Q: What makes this combination a competitive option for treating chronic Hepatitis C?

A: This product offers a once-daily, pangenotypic, oral fixed-dose combination therapy that effectively targets multiple HCV genotypes, simplifying treatment and improving outcomes.

Q: When should these tablets not be used?

A: Avoid using these tablets if there is a history of hypersensitivity to either component or included excipients, and always discuss existing medications to prevent significant drug interactions.

Q: Where can this medication typically be obtained?

A: This prescription-only medication is marketed by licensed pharmaceutical companies and can be obtained through authorized suppliers, traders, or pharmacies in accordance with local health regulations.

Q: What is the main benefit of the dual enzyme inhibition mechanism in this therapy?

A: The pivotal benefit is the targeted inhibition of NS5A and NS5B polymerase enzymes, which significantly reduces HCV replication, leading to improved patient outcomes in chronic infection.

Tell us about your requirement